Dr. Myriam Chalabi, a GI oncologist at the Netherlands Cancer Institute, joins the show after making waves at the latest ESMO Congress for her NICHE-2 study – an assessment of neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer. She shares the initial inspiration to give neoadjuvant immunotherapy for dMMR tumors, the surprisingly positive early results that led to expanding the study, her feelings and expectations leading up to her talk at ESMO, and her reaction to the Twitter phenomenon with the “Chalabi Plot” – how the medical community was in awe of her rare and exceptional waterfall plot. This episode is a good reminder of the value in executing a well-designed clinical trial and the benefits that patients stand to gain from good science.
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
